These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 9264568)

  • 21. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
    Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
    Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iatrogenic endometrial megapolyps in women with breast carcinoma.
    Berezowsky J; Chalvardjian A; Murray D
    Obstet Gynecol; 1994 Oct; 84(4 Pt 2):727-30. PubMed ID: 9205466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
    Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
    Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
    Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
    Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid receptor expression in endometria from women treated with tamoxifen.
    Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
    Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gynecologic tumors in tamoxifen-treated women with breast cancer.
    Seoud MA; Johnson J; Weed JC
    Obstet Gynecol; 1993 Aug; 82(2):165-9. PubMed ID: 8393156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of tamoxifen of endometrium].
    Bai P; Sun J; Zhang K
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):226-8. PubMed ID: 11783367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen and endometrial cancer.
    Segna RA; Dottino PR; Deligdisch L; Cohen CJ
    Mt Sinai J Med; 1992 Oct; 59(5):416-8. PubMed ID: 1435840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients.
    Robinson DC; Bloss JD; Schiano MA
    Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
    Kavak ZN; Binöz S; Ceyhan N; Pekin S
    Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients.
    Cohen I; Rosen DJ; Shapira J; Cordoba M; Gilboa S; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1994 Feb; 52(2):185-90. PubMed ID: 8314137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
    Lee M; Piao J; Jeon MJ
    Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
    Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
    AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian volume in postmenopausal breast cancer patients treated with tamoxifen.
    Cohen I; Altaras MM; Beyth Y; Zalel Y; Shapira J; Yigael D; Tepper R
    Gynecol Oncol; 1997 Jan; 64(1):105-8. PubMed ID: 8995556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.